Celnova Pharma -

Enter your search

PRODUCTS

CENTRAL NERVOUS SYSTEM

Celnova Pharma aims to preserve and improve the lives of people facing serious medical conditions. Our development and commercial efforts are completely focused in specialty drugs, providing patients a wide range of therapies for treatment.

WARNING!
In Argentina, all communication related to medicinal products sold under prescription is regulated by the ANMAT. The product information included in this website is the one contained in the last approved prospectus by the regulatory authority, and it is offered only for informative or educational purposes, without commercial purposes. It does not intend to replace the opinions and recommendations of health professionals, who are the ones who must make the decisions regarding the prescribing information, taking into account the unique characteristics of each patient.

PRODUCTS

Apokinon ®

From France

Drug: apomorphine hydrochloride 30mg/3ml

Pharmaceutical form: solution for injection

Presentation: case containing one multipledose pen injector

Product availability: Argentina

Authorized indications: The treatment of motor fluctuations (‘on-off’ phenomena) in patients with Parkinson’s disease which are not sufficiently controlled by oral anti-Parkinson medication.

Anafranil ®

Drug: clomipramine 75mg, 25mg

Pharmaceutical form: PR capsules 75mg, capsules 25mg

Presentation: container with 20 PR capsules, blister containing 30 25mg capsules

Product availability: Argentina

Authorized indications:

Adults

  • Depression
  • Obsessive-compulsive disorders
  • Phobias and panic disorders
  • Cataplexy associated with narcolepsy
  • Chronic pain

Children

  • Obsessive-compulsive disorders
  • Nocturnal enuresis

® = Registered Trademark

Levenova ®

Drug: levetiracetam 500mg, 1000mg

Pharmaceutical form: coated tablets

Presentation: container with 30 or 60 coated tablets

Product availability: Argentina

Authorized indications:

LEVENOVA is indicated as monotherapy in the treatment of partial onset seizures in patients 16 years of age and older with a new epilepsy diagnosis.

LEVENOVA is indicated for adjunctive therapy in the treatment of:

  • Partial onset seizures in patients 1 month of age and older with epilepsy.
  • Myoclonic seizures in patients 12 years of age and older with Juvenile Myoclonic Epilepsy.
  • Primary generalized tonic-clonic seizures in patients 12 years of age and older with Idiopathic Generalized Epilepsy.

® = Registered Trademark

DISEASE AREAS